March 21, 2023
3 min watch
Save
VIDEO: Combo therapy ‘very effective’ in TALAPRO-2 trial
In this video, Shilpa Gupta, MD, Director of the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data presented from the TALAPRO-2 trial, presented at ASCO Genitourinary Cancers Symposium.
Gupta goes in-depth on the data from the trial, which studied the combination of poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna, Pfizer) and enzalutamide (Xtandi; Astellas, Pfizer) in an unselected population of patients with metastatic castration-resistant prostate cancer (mCRPC).
“It will remain to be seen what the approval indication is, but it’s very encouraging that this combination was very effective,” Gupta said.
Reference:
- Agarwal N, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: ASCO Genitourinary Cancers Symposium, Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Gupta reports consulting for AVEO, EMD Serono, Gilead Sciences, Guardant Health, Loxo/Lilly, Merck and Pfizer.
Read more about